Ninth Cooley's Anemia Symposium

描述(由申请人提供)： 纽约科学院(NYAS)和库利贫血基金会正在筹划一场为期3.5天的重要会议，名为“第九届库利贫血研讨会”。本次会议将于2009年10月21日至24日在纽约市的纽约科学院会议中心举行。这笔赠款的主要研究员是加利福尼亚州奥克兰儿童医院和研究中心的血液学/肿瘤学主任Elliott Vichinsky医学博士。科学组织委员会的联合主席是Ellis Neufeld，医学博士，副主任，分部。波士顿儿童医院血液科/肿瘤科。 第九届库利贫血研讨会的科学目标包括介绍和传播当前的发现，并讨论地中海贫血基础和临床研究的未来方向。地中海贫血是一种导致贫血的遗传性疾病。该计划将涉及以下方面的最新进展：1)铁调节和新陈代谢；2)基因调节和治疗；3)营养和抗氧化疗法；4)铁超载和螯合疗法；5)铁成像；6)干细胞移植的新进展；7)血红蛋白F的新疗法；8)心脏功能障碍；9)地中海贫血的临床症状和疾病严重程度；以及10)成人地中海贫血患者。 这次研讨会将整合基础科学和临床研究，以便临床研究人员和临床医生能够相互了解地中海贫血的最新进展。参与者将包括成熟的和年轻的职业科学家，为年轻科学家进入这一领域提供了一个平台。此外，预计本次会议将加强互补性研究小组之间的交流和后续合作。 与会者应了解地中海贫血的分子生物学、病理生理学、流行病学、临床护理和心理社会管理。主旨演讲、讲座、研讨会、小组讨论和海报演示将全面概述地中海贫血的理解和治疗进展。我们预计这次会议将吸引在分子生物学、细胞生物学、血液学、骨髓和干细胞移植、流行病学、铁生物化学和络合以及输血医学领域工作的高级研究人员、博士后研究员和行业科学家的广泛参与。(摘要结束)

DESCRIPTION (provided by applicant): The New York Academy of Sciences (NYAS) and Cooley's Anemia Foundation are planning an important 3.5-day conference entitled, "Ninth Cooley's Anemia Symposium." This meeting will be held in October, 21-24, 2009 at the New York Academy of Sciences Conference Center in New York City. The principal investigator for this grant is Elliott Vichinsky MD, Director, Hematology/Oncology at the Children's Hospital and Research Center in Oakland, CA. Co-chair on the scientific organizing committee is Ellis Neufeld, MD, PhD, Associate Chief, Div. Of Hematology/Oncology, Children's Hospital Boston. The scientific goals of the Ninth Cooley's Anemia Symposium involve the presentation and dissemination of current findings, and discussing future directions for basic and clinical research in thalassemia, genetic disorders that cause anemia. The program will address recent advances in: 1) Iron Regulation and Metabolism; 2) Gene Regulation and Therapy; 3) Nutrition and Antioxidant Therapies; 4) Iron Overload and Chelation Therapy; 5) Iron Imaging; 6) New Advances In Stem Cell Transplantation; 7) New Therapy For Hemoglobin F; 8) Cardiac Dysfunction; 9) Clinical Syndromes in Thalassemia and Disease Severity; and 10) The Adult Thalassemia Patient. The symposium will integrate basic science and clinical research so that both bench researchers and clinicians can develop a mutual understanding of recent progress in thalassemia. Participants will include both established and young career scientists, providing a platform for young scientists to enter this field. Furthermore, this conference is expected to increase communication and subsequent collaboration between complimentary research groups. Conference attendees should achieve an understanding of the molecular biology, pathophysiology, epidemiology, clinical care and psychosocial management of thalassemic disorders. A combination of keynote addresses, lectures, workshops, panel discussions, and poster presentations will provide a comprehensive overview of progress in the understanding and treatment of thalassemia. We anticipate that the conference will attract wide participation among senior investigators, post-doctoral fellows, and industry scientists working in the fields of molecular biology, cell biology, hematology, bone marrow & stem cell transplantation, epidemiology, iron biochemistry & chelation, and transfusion medicine. (End of Abstract)